Opinion|Videos|October 29, 2024
Barriers to VMS Treatment and Impact on Long-Term Health
Key Takeaways
- Misconceptions about menopause and lack of awareness among healthcare providers contribute to under-treatment of VMS in menopausal women.
- Patient resistance to HRT and nonhormonal treatments like SSRIs and gabapentin is driven by concerns about side effects and long-term risks.
Panelists discuss how underlying factors, including patient resistance to conventional treatments and the stigma surrounding menopause, contribute to the persistent undertreatment of vasomotor symptoms (VMS), which can severely impact women’s quality of life and increase their risk for long-term health issues such as cardiovascular disease and Alzheimer disease.
Advertisement
Video content above is prompted by the following:
- What underlying factors do you think contribute to the persistent under-treatment of VMS in menopausal women, despite the high prevalence of these symptoms?
- What factors contribute to patient resistance to conventional VMS treatment options, specifically hormone replacement therapies and nonhormonal therapies such as SSRIs [selective serotonin reuptake inhibitors] and gabapentin?
- How do untreated VMS impact the overall quality of life and long-term health outcomes for women, such as risk for cardiovascular disease and Alzheimer’s disease?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
4
Pricing and Insurance Networks in Outpatient Surgery Markets
5
